Molecular determinants of folate levels after leucovorin administration in colorectal cancer

[1] Carmichael J(2002)Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3617-3627

[2] Popiela T(2002)Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3605-3616

[3] Radstone D(2006)Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06 J Clin Oncol 24 2059-2064

[4] Falk S(2003)5-Fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330-338

[5] Borner M(1991)Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously J Natl Cancer Inst 83 1806-1812

[6] Oza A(1990)Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts Cancer Res 50 3940-3946

[7] Skovsgaard T(1990)Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts Cancer Res 50 3493-3502

[8] Munier S(1997)Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice Biochem Pharmacol 53 1197-1202

[9] Martin C(2001)Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients Clin Cancer Res 7 517-523

[10] Douillard JY(2004)Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV J Clin Oncol 22 3466-3474

[1] Carmichael J(2002)Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3617-3627

[2] Popiela T(2002)Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3605-3616

[3] Radstone D(2006)Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06 J Clin Oncol 24 2059-2064

[4] Falk S(2003)5-Fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330-338

[5] Borner M(1991)Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously J Natl Cancer Inst 83 1806-1812

[6] Oza A(1990)Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts Cancer Res 50 3940-3946

[7] Skovsgaard T(1990)Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts Cancer Res 50 3493-3502

[8] Munier S(1997)Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice Biochem Pharmacol 53 1197-1202

[9] Martin C(2001)Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients Clin Cancer Res 7 517-523

[10] Douillard JY(2004)Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV J Clin Oncol 22 3466-3474